Charles W. Newton - Feb 9, 2024 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Chief Financial Officer
Signature: /s/ Matthew Lang, as Attorney-in-Fact
Stock symbol: LYEL
Transactions as of: Feb 9, 2024
Transactions value $: $0
Form type: 4
Date filed: 2/13/2024, 08:19 PM
Previous filing: Nov 20, 2023
Next filing: Mar 25, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Award	$0	+40K	+458.24%	$0.00	48.7K	Feb 9, 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYEL	Stock Option (right to buy)	Award	$0	+400K		$0.00	400K	Feb 9, 2024	Common Stock	400K	$1.80	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2	Includes 2,941 shares acquired on May 18, 2022, 5,787 shares acquired on May 18, 2023 and 1 share acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan.
F3	12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months.